Carisma Therapeutics Announces First Patient Dosed In Phase 1 Study of CT-0508 In Combination With KEYTRUDA In Patients With HER2 Overexpressing Solid Tumors
Portfolio Pulse from Happy Mohamed
Carisma Therapeutics (NASDAQ:CARM) has announced the first patient has been dosed in its Phase I clinical trial of CT-0508 in combination with Merck's KEYTRUDA for the treatment of HER2 overexpressing cancers. The trial aims to test the safety and tolerability of the treatment. Pre-clinical data showed improved tumor control and overall survival when both therapies were used together. The patient's cells were manufactured at the Novartis Cell Therapy Site, marking the first clinical product from Carisma's collaboration with Novartis.
June 28, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carisma Therapeutics has begun a Phase I trial of CT-0508 in combination with Merck's KEYTRUDA. The first patient has been dosed, marking a significant step in Carisma's collaboration with Novartis.
The news of the first patient being dosed in the Phase I trial of CT-0508 in combination with KEYTRUDA is a positive development for Carisma Therapeutics. This marks progress in their collaboration with Novartis and could potentially lead to positive outcomes in the treatment of HER2 overexpressing cancers. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100